Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
66
ARMP Quote, Financials, Valuation and Earnings
Last price:
$11.49
Seasonality move
:
0.11%
Day range:
$10.50 - $11.81
52-week range:
$0.90 - $16.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
89.25x
P/B ratio:
--
Volume:
33.3K
Avg. volume:
52.5K
1-year change:
417.31%
Market cap:
$391.7M
Revenue:
$5.2M
EPS (TTM):
-$1.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARMP
Armata Pharmaceuticals, Inc.
|
$740K | -$0.19 | -40.08% | -177.23% | $15.00 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$39.00 | -- | -94.17% | $4.0000 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARMP
Armata Pharmaceuticals, Inc.
|
$10.76 | $15.00 | $391.7M | -- | $0.00 | 0% | 89.25x |
|
AGEN
Agenus, Inc.
|
$3.33 | $12.33 | $120.4M | -- | $0.00 | 0% | 0.84x |
|
CRIS
Curis, Inc.
|
$1.14 | $14.00 | $14.7M | -- | $0.00 | 0% | 1.09x |
|
LADX
LadRx Corp.
|
$0.1100 | -- | $54.5K | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.30 | $5.50 | $41.6M | -- | $0.00 | 0% | 4.85x |
|
WINT
Windtree Therapeutics, Inc.
|
$0.0106 | $4.0000 | $357.3K | 0.00x | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 2.254 | 164.57% | 0.11x |
|
AGEN
Agenus, Inc.
|
510.35% | 3.128 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.079 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.970 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -3.087 | 0.02% | 1.22x |
|
WINT
Windtree Therapeutics, Inc.
|
974.23% | 2.628 | 568.87% | 0.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
WINT
Windtree Therapeutics, Inc.
|
-$360K | -$3.8M | -320.18% | -760.4% | -- | -$6.4M |
Armata Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ARMP or AGEN?
Agenus, Inc. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of -116.82%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About ARMP or AGEN?
Armata Pharmaceuticals, Inc. has a consensus price target of $15.00, signalling upside risk potential of 39.41%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that Agenus, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Agenus, Inc. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARMPArmata Pharmaceuticals, Inc.2 0 0 AGENAgenus, Inc.2 1 0 -
Is ARMP or AGEN More Risky?
Armata Pharmaceuticals, Inc. has a beta of 1.304, which suggesting that the stock is 30.4% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.
-
Which is a Better Dividend Stock ARMP or AGEN?
Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARMP or AGEN?
Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 89.25x versus 0.84x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARMPArmata Pharmaceuticals, Inc.89.25x -- $1.2M -$26.7M AGENAgenus, Inc.0.84x -- $30.2M $63.9M
-
Which has Higher Returns ARMP or CRIS?
Curis, Inc. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of -243.36%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About ARMP or CRIS?
Armata Pharmaceuticals, Inc. has a consensus price target of $15.00, signalling upside risk potential of 39.41%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1128.07%. Given that Curis, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Curis, Inc. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARMPArmata Pharmaceuticals, Inc.2 0 0 CRISCuris, Inc.4 0 0 -
Is ARMP or CRIS More Risky?
Armata Pharmaceuticals, Inc. has a beta of 1.304, which suggesting that the stock is 30.4% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.020, suggesting its more volatile than the S&P 500 by 202.024%.
-
Which is a Better Dividend Stock ARMP or CRIS?
Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARMP or CRIS?
Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 89.25x versus 1.09x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARMPArmata Pharmaceuticals, Inc.89.25x -- $1.2M -$26.7M CRISCuris, Inc.1.09x -- $3.2M -$7.7M
-
Which has Higher Returns ARMP or LADX?
LadRx Corp. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of --. Armata Pharmaceuticals, Inc.'s return on equity of -- beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About ARMP or LADX?
Armata Pharmaceuticals, Inc. has a consensus price target of $15.00, signalling upside risk potential of 39.41%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 408990.91%. Given that LadRx Corp. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe LadRx Corp. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARMPArmata Pharmaceuticals, Inc.2 0 0 LADXLadRx Corp.0 0 0 -
Is ARMP or LADX More Risky?
Armata Pharmaceuticals, Inc. has a beta of 1.304, which suggesting that the stock is 30.4% more volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.406, suggesting its less volatile than the S&P 500 by 59.371%.
-
Which is a Better Dividend Stock ARMP or LADX?
Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARMP or LADX?
Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are larger than LadRx Corp. quarterly revenues of --. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 89.25x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARMPArmata Pharmaceuticals, Inc.89.25x -- $1.2M -$26.7M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns ARMP or PSTV?
Plus Therapeutics, Inc. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of -316.61%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About ARMP or PSTV?
Armata Pharmaceuticals, Inc. has a consensus price target of $15.00, signalling upside risk potential of 39.41%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1716.98%. Given that Plus Therapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARMPArmata Pharmaceuticals, Inc.2 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is ARMP or PSTV More Risky?
Armata Pharmaceuticals, Inc. has a beta of 1.304, which suggesting that the stock is 30.4% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.
-
Which is a Better Dividend Stock ARMP or PSTV?
Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARMP or PSTV?
Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 89.25x versus 4.85x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARMPArmata Pharmaceuticals, Inc.89.25x -- $1.2M -$26.7M PSTVPlus Therapeutics, Inc.4.85x -- $1.4M -$4.4M
-
Which has Higher Returns ARMP or WINT?
Windtree Therapeutics, Inc. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of --. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.
Company Gross Margin Earnings Per Share Invested Capital ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M -
What do Analysts Say About ARMP or WINT?
Armata Pharmaceuticals, Inc. has a consensus price target of $15.00, signalling upside risk potential of 39.41%. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 37635.85%. Given that Windtree Therapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARMPArmata Pharmaceuticals, Inc.2 0 0 WINTWindtree Therapeutics, Inc.0 0 0 -
Is ARMP or WINT More Risky?
Armata Pharmaceuticals, Inc. has a beta of 1.304, which suggesting that the stock is 30.4% more volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.169%.
-
Which is a Better Dividend Stock ARMP or WINT?
Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ARMP or WINT?
Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are larger than Windtree Therapeutics, Inc. quarterly revenues of --. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 89.25x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARMPArmata Pharmaceuticals, Inc.89.25x -- $1.2M -$26.7M WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
